These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 36427418

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Alanazi W, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Mattsson J, Michelis FV.
    Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
    [Abstract] [Full Text] [Related]

  • 3. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
    Barkhordar M, Kasaeian A, Janbabai G, Mousavi SA, Fumani HK, Tavakoli S, Bahri T, Ghavamzadeh A, Vaezi M.
    Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
    Cao J, Xu X, Lu Y, Wang T, Chen D, Li S, Liu X, Ye P, Zheng ZZ, Pei R.
    Hematology; 2023 Dec; 28(1):2223873. PubMed ID: 37347232
    [Abstract] [Full Text] [Related]

  • 6. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
    Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y, Wang X, Guo S, Zhan X, Fu Y, Song Y, Zhou J.
    Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation.
    Kim DH, Shin DY, Koh Y, Kim I, Yoon SS, Byun JM, Hong J.
    Sci Rep; 2024 Jun 16; 14(1):13885. PubMed ID: 38880835
    [Abstract] [Full Text] [Related]

  • 9. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
    Wang Y, Wu DP, Liu QF, Xu LP, Liu KY, Zhang XH, Yu WJ, Xu Y, Huang F, Huang XJ.
    J Hematol Oncol; 2019 Sep 03; 12(1):88. PubMed ID: 31481121
    [Abstract] [Full Text] [Related]

  • 10. Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies.
    Abadir E, Othman J, Kwan J, Gottlieb DJ, Kennedy GA, Bajel A, Doocey R, Perera T, Watson AM, Bardy PG, Greenwood M, Curtis DJ, Tran S, Moore J, Hamad N.
    Transplant Cell Ther; 2024 Mar 03; 30(3):334.e1-334.e7. PubMed ID: 38029962
    [Abstract] [Full Text] [Related]

  • 11. Haploidentical Cord Blood Transplantation with 8 mg/kg Antithymocyte Globulin as Graft-versus-Host Disease Prophylaxis Compared to Haploidentical Transplantation with 10 mg/kg Antithymocyte Globulin in the Treatment of Acute Leukemia.
    Yuan F, Li G, Li M, Wei X, Fu Y.
    Transplant Cell Ther; 2023 Dec 03; 29(12):771.e1-771.e10. PubMed ID: 37748539
    [Abstract] [Full Text] [Related]

  • 12. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DDH, Lipton JH, Kumar R, Messner H, Viswabandya A.
    Biol Blood Marrow Transplant; 2018 Nov 03; 24(11):2259-2264. PubMed ID: 30009980
    [Abstract] [Full Text] [Related]

  • 13. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors.
    Li T, He Q, Yang J, Cai Y, Huang C, Xu X, Qiu H, Niu J, Zhou K, Zhang Y, Xia X, Wei Y, Shen C, Ding X, Tong Y, Wan L, Song X.
    Cell Transplant; 2022 Nov 03; 31():9636897221139103. PubMed ID: 36433646
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, Gerbitz A, Socié G, Afanasyev B, Ciceri F, Meijer E, Koc Y, Cornelissen JJ, Huynh A, Ozdogu H, Maertens J, Paul F, Labussière-Wallet H, Ruggeri A, Aljurf M, Bazarbachi A, Savani B, Nagler A, Mohty M.
    Cancer; 2021 Jan 15; 127(2):209-218. PubMed ID: 33119152
    [Abstract] [Full Text] [Related]

  • 16. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Chang YJ, Wang Y, Mo XD, Zhang XH, Xu LP, Yan CH, Chen H, Chen YH, Chen Y, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ.
    Cancer; 2017 Aug 01; 123(15):2881-2892. PubMed ID: 28301690
    [Abstract] [Full Text] [Related]

  • 17. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, Ko SH, Seol M, Lee YS, Kang YA, Jeon M, Baek S, Kang YL, Kim SH, Yun SC, Kim H, Jo JC, Choi Y, Joo YD, Lim SN.
    Biol Blood Marrow Transplant; 2017 Sep 01; 23(9):1555-1566. PubMed ID: 28552421
    [Abstract] [Full Text] [Related]

  • 18. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
    Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S, Koc Y, Bramanti S, Kulagin A, Kwon M, Sica S, Sanz J, Brissot E, Nagler A, Ciceri F, Mohty M.
    Cancer; 2024 Sep 15; 130(18):3123-3136. PubMed ID: 38758817
    [Abstract] [Full Text] [Related]

  • 19. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR, Guillaume T, Willem C, Legrand N, Gagne K, Cesbron A, Gendzekhadze K, Peterlin P, Garnier A, Le Bourgeois A, Béné MC, Chevallier P, Retière C.
    J Immunol; 2020 Sep 01; 205(5):1441-1448. PubMed ID: 32747504
    [Abstract] [Full Text] [Related]

  • 20. Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients.
    Pan M, Wu Y, Yang L, Zhu P, Shi J, Lai X, Liu L, Zhao Y, Yu J, Huang H, Luo Y.
    Ann Hematol; 2024 Aug 01; 103(8):3105-3119. PubMed ID: 38829409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.